PMID- 30032061
OWN - NLM
STAT- MEDLINE
DCOM- 20180924
LR  - 20180924
IS  - 1532-1967 (Electronic)
IS  - 0305-7372 (Linking)
VI  - 69
DP  - 2018 Sep
TI  - Optimisation of treatment with lenvatinib in radioactive iodine-refractory 
      differentiated thyroid cancer.
PG  - 164-176
LID - S0305-7372(18)30113-0 [pii]
LID - 10.1016/j.ctrv.2018.06.019 [doi]
AB  - Lenvatinib has been approved for the treatment of advanced differentiated thyroid 
      cancer (DTC) refractory to radioactive iodine (RAI) following the results of the 
      SELECT trial which demonstrated a significant increase in progression-free 
      survival and a high response rates. The data reported for lenvatinib in 
      RAI-refractory DTC (RAI-R DTC) are the most significant to date in this patient 
      population, with a RECIST objective response rate above 60% and almost 80% 
      reduction in the risk of disease progression. Because the first indication in 
      oncology for lenvatinib is specifically in RAI-R DTC, a period of familiarisation 
      with its safety and efficacy profile is required. This review includes a series 
      of specific recommendations for optimising the management of RAI-R DTC with 
      lenvatinib, as well as specific guidelines for minimising the incidence and 
      severity of adverse events (AEs), which enable dose intensity to be increased and 
      this way maximise the benefits of the drug in the patient population treated. 
      These recommendations were defined at a meeting of experts of different 
      specialities, reviewing available scientific evidence on the drug, as well as 
      their own direct personal experience in daily clinical practice. For toxicity to 
      be properly managed, a multidisciplinary approach is required in which the 
      different medical services, nursing staff and the patient and their careers are 
      all involved. It is essential to assess the suitability of patients who are 
      candidates for lenvatinib, as well as their clinical and physiological status 
      prior to treatment. They must then be closely monitored to prevent and detect 
      possible AEs. The main objective should be to maintain the dose that obtains the 
      maximum therapeutic effect, discontinuing the treatment only if the toxicity 
      becomes unmanageable or there is no clinical benefit.
CI  - Copyright (c) 2018 Elsevier Ltd. All rights reserved.
FAU - Capdevila, Jaume
AU  - Capdevila J
AD  - Medical Oncology Department, Gastrointestinal and Endocrine Tumor Unit, Vall 
      d'Hebron, University Hospital, Barcelona, Spain. Electronic address: 
      jacapdevila@vhebron.net.
FAU - Newbold, Kate
AU  - Newbold K
AD  - Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
FAU - Licitra, Lisa
AU  - Licitra L
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
FAU - Popovtzer, Aron
AU  - Popovtzer A
AD  - Davidoff Cancer Center, Tel Aviv Medical School Sackler, Israel.
FAU - Moreso, Francesc
AU  - Moreso F
AD  - Renal Transplant Unit, Nephrology Department, Hospital Universitari Vall 
      d'Hebron. Autonomous University of Barcelona, Barcelona, Spain.
FAU - Zamorano, Jose
AU  - Zamorano J
AD  - Head of Cardiology, University Hospital Ramon y Cajal, Madrid, Spain.
FAU - Kreissl, Michael
AU  - Kreissl M
AD  - Department of Nuclear Medicine, Otto-von-Guericke-University/Medical Faculty, 
      Department of Radiology and Nuclear Medicine, Magdeburg, Germany.
FAU - Aller, Javier
AU  - Aller J
AD  - Endocrinology Department University Hospital Puerta de Hierro, Madrid, Spain.
FAU - Grande, Enrique
AU  - Grande E
AD  - Medical Oncology Department, MD Anderson Cancer Center Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180702
PL  - Netherlands
TA  - Cancer Treat Rev
JT  - Cancer treatment reviews
JID - 7502030
RN  - 0 (Iodine Radioisotopes)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinolines)
RN  - EE083865G2 (lenvatinib)
SB  - IM
MH  - Adenocarcinoma/*drug therapy/pathology/radiotherapy
MH  - Cell Differentiation/*drug effects/radiation effects
MH  - Humans
MH  - Iodine Radioisotopes/*adverse effects
MH  - Phenylurea Compounds/*therapeutic use
MH  - Prognosis
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Quinolines/*therapeutic use
MH  - Radiation Tolerance/*drug effects
MH  - Thyroid Neoplasms/*drug therapy/pathology/radiotherapy
OTO - NOTNLM
OT  - Adverse events
OT  - Hypertension
OT  - Lenvatinib
OT  - Patient Safety
OT  - Protein kinase inhibitors
OT  - Proteinuria
OT  - Thyroid neoplasms
EDAT- 2018/07/23 06:00
MHDA- 2018/09/25 06:00
CRDT- 2018/07/23 06:00
PHST- 2017/12/18 00:00 [received]
PHST- 2018/06/28 00:00 [revised]
PHST- 2018/06/29 00:00 [accepted]
PHST- 2018/07/23 06:00 [pubmed]
PHST- 2018/09/25 06:00 [medline]
PHST- 2018/07/23 06:00 [entrez]
AID - S0305-7372(18)30113-0 [pii]
AID - 10.1016/j.ctrv.2018.06.019 [doi]
PST - ppublish
SO  - Cancer Treat Rev. 2018 Sep;69:164-176. doi: 10.1016/j.ctrv.2018.06.019. Epub 2018 
      Jul 2.